Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma

被引：0
|
作者：
Oliver F Bathe
Scot Dowden
Francis Sutherland
Elijah Dixon
Charles Butts
David Bigam
Barb Walley
Dean Ruether
Scott Ernst
机构：
[1] University of Calgary,Department of Surgery
[2] University of Calgary,Department of Oncology
[3] University of Alberta,Department of Surgery
[4] University of Alberta,Department of Oncology
[5] London Regional Cancer Centre,Department of Oncology
来源：
BMC Cancer | / 4卷
关键词：
Liver Metastasis; Hepatic Resection; Radiofrequency Ablation; Preoperative Chemotherapy; Metastatic Colorectal Cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases
    Yamaguchi, Tatsuro
    Matsumoto, Hiroshi
    Yasutome, Michiya
    Mori, Takeo
    Takahashi, Keiichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (03) : 629 - 635
  • [22] CETUXIMAB (CMAB) PLUS CPT-11/5-FLUOROURACIL (5-FU)/LEUCOVORIN(FA)/OXALIPLATIN (L-OHP) (CPT-11-FFL) IN UNRESECTABLE COLORECTAL LIVER METASTASES (CLM): POCHER TRIAL TOXICITY RESULTS
    Torsello, A.
    Garufi, C.
    Tumolo, S.
    Mottolese, M.
    Campanella, C.
    Zeuli, M.
    Sperduti, I
    Pizzi, G.
    Ettorre, G.
    ANNALS OF ONCOLOGY, 2009, 20 : 62 - 63
  • [23] Alternating hepatic artery chronotherapy with CPT-11 and systemic chronotherapy with 5-FU/FA plus carboplatin for metastatic colorectal cancer confined to the liver: A phase II study
    Shimonov, M
    Hayat, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 297S - 297S
  • [24] Extended phase I study of a weekly schedule of irinotecan (CPT-11), leucovorin and infusional 5-FU as first-line chemotherapy in metastatic colorectal cancer.
    Vanhoefer, U
    Harstrick, A
    Achterrath, W
    Lipp, R
    Mayer, S
    Schöffski, P
    Köhne, CH
    Hossfeld, KD
    Wilke, H
    Seeber, S
    CLINICAL CANCER RESEARCH, 1999, 5 : 3799S - 3799S
  • [25] POCHER (preoperative chemotherapy for hepatic resection) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin(FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM)
    Garufi, C.
    Torsello, A.
    Tumolo, S.
    Mottolese, M.
    Campanella, C.
    Zeuli, M.
    Lo Re, G.
    Sperduti, I.
    Pizzi, G.
    Ettorre, G. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] Irinotecan (CPT-11) in 5-FU pretreated advanced colorectal cancer: Results in 174 expanded access patients
    Iveson, T
    Eggleton, SPH
    Hickish, T
    Cunningham, D
    Maughan, T
    Harper, P
    ANNALS OF ONCOLOGY, 1998, 9 : 36 - 37
  • [27] A multicenter phase II study of irinotecan (CPT-11) and bolus 5-fluorouracil (5FU)/I-leucovorin (I-LV) in patients with metastatic colorectal cancer
    Fujishima, H
    Makiyama, A
    Miyanaga, O
    Ueda, A
    Esaki, T
    Mitsugi, K
    Baba, E
    Kusaba, H
    Harada, M
    Nakano, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 306S - 306S
  • [28] Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX
    F Recchia
    G Saggio
    A Nuzzo
    A Lalli
    L Di Lullo
    A Cesta
    S Rea
    British Journal of Cancer, 2004, 91 : 1442 - 1446
  • [29] Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX
    Recchia, F
    Saggio, G
    Nuzzo, A
    Lalli, A
    Di Lullo, L
    Cesta, A
    Rea, S
    BRITISH JOURNAL OF CANCER, 2004, 91 (08) : 1442 - 1446
  • [30] A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma
    Gennatas, C.
    Papaxoinis, G.
    Michalaki, V.
    Mouratidou, D.
    Andreadis, Ch.
    Tsavaris, N.
    Pafiti, A.
    JOURNAL OF CHEMOTHERAPY, 2006, 18 (05) : 538 - 544
12345